Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24560758)

  • 1. Does family history of prostate cancer affect outcomes following radiotherapy?
    Bagshaw H; Ruth K; Horwitz EM; Chen DY; Buyyounouski MK
    Radiother Oncol; 2014 Feb; 110(2):229-34. PubMed ID: 24560758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy.
    Zumsteg ZS; Spratt DE; Romesser PB; Pei X; Zhang Z; Polkinghorn W; McBride S; Kollmeier M; Yamada Y; Zelefsky MJ
    Eur Urol; 2015 Jun; 67(6):1009-1016. PubMed ID: 25308970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization.
    Foster B; Jackson W; Foster C; Dess R; Abu-Isa E; McLaughlin PW; Merrick G; Hearn J; Spratt D; Liauw S; Hamstra D
    Am J Clin Oncol; 2019 Apr; 42(4):382-390. PubMed ID: 30724780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.
    Kupelian PA; Buchsbaum JC; Patel C; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):704-11. PubMed ID: 11849793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
    Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Feng FY; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):721-8. PubMed ID: 23664325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).
    Randazzo M; Müller A; Carlsson S; Eberli D; Huber A; Grobholz R; Manka L; Mortezavi A; Sulser T; Recker F; Kwiatkowski M
    BJU Int; 2016 Apr; 117(4):576-83. PubMed ID: 26332304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy.
    Buyyounouski MK; Hanlon AL; Horwitz EM; Pollack A
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):59-66. PubMed ID: 17919840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
    Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy.
    Foster CC; Jackson WC; Foster BC; Johnson SB; Feng FY; Hamstra DA
    Radiat Oncol; 2014 Nov; 9():245. PubMed ID: 25424123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial prostate cancer: a different disease?
    Kupelian PA; Klein EA; Witte JS; Kupelian VA; Suh JH
    J Urol; 1997 Dec; 158(6):2197-201. PubMed ID: 9366343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer.
    D'Ambrosio DJ; Hanlon AL; Al-Saleem T; Feigenberg SJ; Horwitz EM; Uzzo RG; Pollack A; Buyyounouski MK
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1082-7. PubMed ID: 17241749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death.
    Alcantara P; Hanlon A; Buyyounouski MK; Horwitz EM; Pollack A
    Cancer; 2007 Jan; 109(1):41-7. PubMed ID: 17133416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggressiveness of familial prostate cancer.
    Kupelian PA; Reddy CA; Reuther AM; Mahadevan A; Ciezki JP; Klein EA
    J Clin Oncol; 2006 Jul; 24(21):3445-50. PubMed ID: 16849760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Race as an independent predictor of outcome after treatment for localized prostate cancer.
    Sohayda CJ; Kupelian PA; Altsman KA; Klein EA
    J Urol; 1999 Oct; 162(4):1331-6. PubMed ID: 10492191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era.
    Pollack A; Smith LG; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):507-12. PubMed ID: 10974469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.